In December 2014 BioGaia reported its decision to invest SEK 12 million in
MetaboGen AB, Gothenburg, Sweden. The investment should be made over a two year
period.
The first investment of SEK 4 million took place in December 2014 and as
MetaboGen has reached the agreed milestones the second investment of SEK 4
million was made today.
BioGaia thereafter owns 27% of the share capital of MetaboGen, and if further
milestones will be reached, the last investment of SEK 4 million will take place
at the end of 2016. BioGaia's share of the company will then be 35%.
MetaboGen is a research company, which was founded in 2011 in Gothenburg by
Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B
Nielsen at Chalmers University of Technology together with GU Holding, which
commercializes research results and develops companies linked to the University
of Gothenburg. MetaboGen researches in metagenomics, the research intensive and
fast developing field of gene sequencing of all genes in the microbial
communities of for example the human gut to find previously unknown members and
patterns of the microbial diversity related to health and disease. The aim is to
develop new treatments and products for different metabolic and other microbial
associated diseases by influencing large parts of the microbiota.
Peter Rothschild is chairman of the board and Sara Malcus is president in
MetaboGen AB.
For further information please see BioGaia's press release from 1 December 2014
on BioGaia's website: www.biogaia.com/press-releases
Latest press releases from BioGaia
2015-10-26 BioGaia signs exclusive agreement in Sri Lanka
2015-10-23 BioGaia AB Interim Management Statement 1 January – 30 September 2015
2015-10-20 BioGaia appoints new Managing Director
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 1 December, 2015 10:00
am CET.
For additional information please contact
Peter Rothschild, President, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
